Case Study In Bioprocess Development [2021] | A Mab A

The study employs tools like Failure Mode and Effects Analysis (FMEA) to assess how process parameters impact CQAs.

The study centers on the transition from "traditional" process development to an enhanced QbD approach. It leverages guidelines from the International Council for Harmonisation (ICH), specifically (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System). A Mab A Case Study In Bioprocess Development

The process begins by identifying the antibody's CQAs—physical, chemical, biological, or microbiological properties that must be within an appropriate limit to ensure safety and efficacy. The study employs tools like Failure Mode and

The is a landmark document in the biopharmaceutical industry, serving as a comprehensive template for applying Quality by Design (QbD) principles to the development of monoclonal antibodies (mAbs) . Published in 2009 by the CMC Biotech Working Group , it simulates the development of a hypothetical IgG1 monoclonal antibody to demonstrate how systematic, risk-based approaches can enhance process understanding and ensure product quality. Core Framework of the A-Mab Study Core Framework of the A-Mab Study